Onychomycosis Due To Dermatophyte — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for onychomycosis due to dermatophyte. 17 active patents protecting 1 drugs from 1+ originators. First major cliff: 2028. Daily refresh.

1
Approved drugs
17
Active US patents
64/100
Avg vulnerability
—
Annual revenue covered

Originators in Onychomycosis Due To Dermatophyte

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Bausch Health 17 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating onychomycosis due to dermatophyte. Each bar = one year. Y-axis scaled to peak year (6 patents).

6
28
5
30
5
34
1
35

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Jublia
EFINACONAZOLE
 Bausch Health 17 64 — 2028-01-03

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11872218 Jublia method of use 88 2028-01-03
11213519 Jublia method of use 83 2028-01-03
10512640 Jublia method of use 75 2028-01-03
9566272 Jublia method of use 75 2028-01-03
9877955 Jublia method of use 75 2028-01-03
8039494 Jublia method of use 73 2030-07-08
11654139 Jublia method of use 70 2034-10-02
10342875 Jublia method of use 62 2034-10-02
10828293 Jublia method of use 62 2034-10-02
10864274 Jublia method of use 62 2034-10-02

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9662394 Jublia formulation 42 2034-10-02
9302009 Jublia formulation 48 2030-10-24
9861698 Jublia formulation 48 2030-07-08
10105444 Jublia formulation 48 2030-07-08
8486978 Jublia formulation 53 2030-10-24
10828369 Jublia formulation 55 2028-01-03
10478601 Jublia method of use 62 2035-04-25
10864274 Jublia method of use 62 2034-10-02
10342875 Jublia method of use 62 2034-10-02
10828293 Jublia method of use 62 2034-10-02

Related